The Advisory Committee on Immunization Practices recommended changes that will likely result in fewer older adults qualifying for insurance coverage for RSV vaccines. They also did not make a recommendation on the use of GSK’s Arexvy vaccine in adults aged 50 to 59 due to insufficient data. Without ACIP and CDC recommendations, insurance companies are unlikely to cover the cost of the vaccine for those in their 50s. The ACIP also recommended RSV shots for people aged 75 and older and those aged 60 to 74 with certain health conditions. The science on vaccine use is evolving, and policy may change in the future.
Source link
CDC panel opts for a go-slow approach on expanding usage of RSV vaccines
